CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
J Neurosurg
; 124(6): 1746-51, 2016 Jun.
Article
em En
| MEDLINE
| ID: mdl-26587656
Palavras-chave
CES1 = carboxylesterase 1; CYP = cytochrome P450; ICAD = intracranial atherosclerotic disease; LOF = loss of function; MI = myocardial infarction; PTAS = percutaneous transluminal angioplasty and stenting; SAMMPRIS = Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis; SNP = single-nucleotide polymorphism; TIA = transient ischemic attack; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease; antiplatelet; intracranial atherosclerotic disease; intracranial stenosis; pharmacogenomics; stroke; transient ischemic attack; vascular disorders
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ticlopidina
/
Inibidores da Agregação Plaquetária
/
Hidrolases de Éster Carboxílico
/
Arteriosclerose Intracraniana
/
Aspirina
/
Citocromo P-450 CYP2C19
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Neurosurg
Ano de publicação:
2016
Tipo de documento:
Article
País de publicação:
Estados Unidos